Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8232478 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 6 Pages |
Abstract
PORT may be an adequate adjuvant therapy for OSCC patients with one or two risk factors of recurrence. The presence of multiple risk factors and lymphatic invasion correlated with poor prognosis, and more aggressive treatment may need to be considered.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Kang-Hsing M.D., Hung-Ming M.D., Chung-Jan M.D., Li-Yu M.D., Shiang-Fu M.D., Chien-Yu M.D., Eric Yen-Chao M.D., I-How M.D., Chun-Ta M.D., Joseph Tung-Chieh M.D., M.H.A.,